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Objective: Obesity is characterized by low levels of adiponectin, an adipocytes derived hormone, and by an
inflammatory component. Endothelial dysfunction is often found in overweight/obesity, diabetes, and
atherosclerosis. Advanced glycation end products (AGEs) induce endothelial dysfunction and are linked to
diabetes and increased atherogenicity and inflammation. The aim of the study was to investigate the possible
link between adiponectin and N(epsilon)-(carboxymethyl) lysine (CML), the predominant adduct of
circulating AGEs in overweight patients, and, in an in vitro model, to test the hypothesis that adiponectin acts
as modulator of endothelial dysfunction, induced by AGEs.
Results: In 108 overweight patients, plasma levels of CML correlated inversely with adiponectin levels. Pre-
incubation of human vein endothelial cells (HUVECs) with physiological concentrations of adiponectin,
followed by stimulation with AGEs, reduced vascular adhesion molecule-1 (VCAM-1) and E-selectin
expression, as assessed by surface enzyme immunoassay.
Conclusions: Taken together, these findings demonstrate an inverse correlation between CML and adiponectin
levels in overweight patients and a protective role of adiponectin on endothelial dysfunction induced by AGEs,
suggesting its key role in the treatment of the vascular complications of obesity/metabolic syndrome.
© 2011 Elsevier Inc. All rights reserved.Introduction
Adiponectin is an adipokine specifically secreted by adipose cells
that plays an important role in the modulation of insulin sensitivity,
inflammation, and endothelial function. Low plasma adiponectin
concentrations are associated with higher prevalence of overweight/
obesity (Arita et al., 1999; Shimabukuro et al., 2003), insulin
resistance (Fernandez-Real et al., 2004), type 2 diabetes (Li et al.,
2009), hypertension (Adamczak et al., 2003), and atherosclerosis.
Adiponectin modulates endothelial cell dysfunction induced by
proinflammatory stimuli, countering the adverse cellular effects of
both increased oxidative stress and cytokine stimulations (Ouchi
et al., 1999).
Endothelial dysfunction has been proposed to be an early and
pivotal event of atherosclerotic disease, providing an important
common denominator between several diseases, such as hyperten-
sion, overweight/obesity (Meyers and Gokce, 2007; Pierce et al.,
2008), and diabetes (Basta et al., 2004; Yonekura et al., 2005).l rights reserved.Advanced glycation end products (AGEs) are a heterogeneous
group of compounds formed by nonenzymatic glycation of proteins
and lipids, whose increased levels contribute to the development of
vascular complications in diabetes, inducing endothelial dysfunction
(Basta et al., 2002; Yonekura et al., 2005). Several mechanisms by
which AGEs lead to endothelial dysfunction have been proposed, such
as the accumulation of AGEs in the extracellular matrix, the binding of
circulating AGEs to the endothelial surface receptor for AGEs (RAGE)
with subsequent generation of reactive oxygen species (ROS), the
cytokine release, and the expression of cell adhesion molecules (Basta
et al., 2004).
Here, we have investigated the possible link between adiponectin
and N(epsilon)-(carboxymethyl) lysine (CML), the predominant
adduct of circulating AGEs, in a group of overweight patients, and
tested the hypothesis that adiponectin may act as endogenous
modulator of endothelial cell dysfunction, induced by AGEs and
evaluated by the expression of adhesion molecules.
Methods
Subjects and blood collection
We analyzed plasma samples collected from 108 subjects without
evidence of either cardiac, hepatic, or renal diseases that previously
participated to another study (Basta et al., 2006). Subjects with a body
mass index (BMI) N25 kg/m2 were stratified according to glucose
Fig. 1. Correlation between adiponectin and CML in control, prediabetic, and diabetic
subjects. Data are expressed as mean±SEM. In the insert is showed the partial
coefficient of correlation (r) and the P-value of the entire group of study subjects.
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either normal (NGT; n=39) or impaired glucose tolerant (IFG and/or
IGT; n=27) or with previous diagnosis of type 2 diabetes (n=42).
Subject characteristics are shown in Table 1. Subjects are non-
smoking, had normal serum creatinine (i.e., b1.2 mg/dl) and did not
take any medication known to affect glucose tolerance. Hypertension
was defined as blood pressure greater than 140/90 mm Hg. The study
protocol was approved by the Institutional Review Board of the
University of Pisa, and all subjects gave written informed consent to
the study.
Blood samples were drawn in tubes without additives, containing
heparin or citrate (for routine biochemistry). For CML and adiponectin
determination, blood samples were collected in tubes containing
Na2EDTA and aprotinin, centrifuged at 4 °C and immediately divided
in aliquots. Plasma and serum samples were stored at −80 °C until
analysis.Determination of plasma adiponectin levels
Plasma levels of total adiponectin were measured by enzyme
immunoassay (LINCO Research Inc., Missouri, USA), according to
manufacturer's instructions.Determination of plasma CML levels
Plasma CML levels were measured in triplicate by an in-house
competitive ELISA using the mouse F(ab′)2 fragment anti-AGE
monoclonal antibody (clone 6D12) (ICN Biochemical Division, Aurora,
OH), as described previously (Kaloudi et al., 2007).Cell culture and experimental design
All experiments were performed in human umbilical vein
endothelial cells (HUVECs), isolated, and grown as described
(Massaro et al., 2002). Before the indicated treatments, the cells
were made quiescent by replacing the growth medium with
UltraCulture Serum-free Medium (BioWhitaker, Walkersville, Inc.,
USA) for 24 h. HUVECs were pretreated with recombinant globular
adiponectin (gAcrp30) expressed in Escherichia coli (Peprotech, Inc.,
Rocky Hill, NJ) for 10 h and then stimulated with AGEs (containing
about 80% CML-adducts), prepared as described (Basta et al., 2002),
for 18 h and 10 h to induce VCAM-1 and E-selectin, respectively, as
validated in our previous study (Basta et al., 2002). Cytotoxicity of
treatment with adiponectin was tested as described in our previousTable 1
Patient characteristics.
Controls
(N=108)
Prediabetics
(N=27)
Diabetics
(N=42)
Gender (female/male) 14/25 4/23 13/29
Age (y) 41±9 47±9* 59±5§,†
BMI (kg·m−2) 27±3 28±4 29±3
HT (yes/no) 28/11 19/8 20/22
MBP (mm Hg) 93±15 97±14 96±9
CML (µg/mL) 43±21 53±29 77±52**,§
Adiponectin (µg/mL) 7±3 6.7±2 5±3*,**
HOMA (mM • pM) 19 [4–41] 23 [3–65] 31±[8–105]§
Fasting plasma glucose (mg/dl) 91±6 107±11§ 149±35§,†
Cholesterol (mg/dl) 186±35 197±33 201±34
HDL (mg/dl) 46±13 43±9 50±14**
Triglycerides (mg/dl) 94±65 110±65 126±48*
HT indicates hypertension; BMI, body mass index; CRP, C-reactive protein; HOMA,
homeostasis model assessment; MBP, mean blood pressure.
Pb0.05 vs. control subjects, ** Pb0.05 vs. prediabetic subjects, § Pb0.001 vs. control
subjects, † Pb0.001 vs. prediabetic subjects.study (Del Turco et al., 2007). All experiments were performed in
triplicate.
Detection of cell surface adhesion molecules
Assay of cell surface molecules was performed by cell surface
enzyme immunoassay as described by us previously (Basta et al.,
2002; Lazzerini et al., 2009).
Statistical analysis
Data normally distributed are given as mean±SD unless specified.
HOMA has a skewed distribution and is expressed as median and
interquartile range. Comparisons of continuous variables were
compared by Student's t-test. A Pearson's correlation test was used
to determine the relationship among variables. Amultivariate analysis
was used to evaluate the correlation between adiponectin and CML
levels after adjustment for age, BMI, HOMA, and mean blood pressure
(MBP). Results are given as partial correlation coefficients. Multiple
differences were evaluated by analysis of variance (ANOVA) followed
by Bonferroni post hoc test. Data were analyzed by StatView 5.0.1
software (SAS, Cary, NC, USA).Fig. 2. Effects of adiponectin on VCAM-1 and E-selectin expression. HUVECs were
pretreated for 10 h with indicated amounts of adiponectin then treated with AGEs
(200 μg/mL) for 18 h (A) and 10 h (B). Data are expressed as mean±SD and are
representative of three independent experiments. *Pb0.001 vs. treatment with AGEs
alone.
75S. Del Turco et al. / Microvascular Research 82 (2011) 73–76Results
Clinical results: correlation between adiponectin and CML plasma levels
The demographic characteristics of the subjects are shown in
Table 1. Of 108 subjects, 39 were normal, 42 were diabetic, and 27
were prediabetic, as resulted by oral glucose tolerance test (OGTT).
Our results showed that adiponectin levels were inversely
associated with insulin resistance [homeostasis model assessment
(HOMA)] (r=−0.286; p=0.045), high density lipoproteins (HDL)
(r=−0.307; p=0.0022), glucose (r=−0.235; p=0.0206), trigly-
cerides (r=−0.228; p=0.0252) and, more interestingly, correlated
inversely with CML levels in all subjects (r=−0.208; p=0.0338),
after adjustment for age, BMI, HOMA, and mean blood pressure
(MBP). This correlation is well represented in Fig. 1, where the
patients were divided into three groups: prediabetic, diabetic, and
normal glucose tolerant subjects.
In vitro results: adiponectin inhibits the AGE-induced endothelial
expression of adhesion molecules
AGEs (200 μg/mL) enhanced VCAM-1 and E-selectin expression as
previously demonstrated by us (Basta et al., 2002). The pretreatment
with physiological concentrations of adiponectin (0.25–0.5–1–5 μg/
mL) for 10 h inhibited the endothelial surface expression of VCAM-1
(Fig. 2A) and E-selectin (Fig. 2B) in concentration-dependent manner.
Adiponectin alone, also when the highest concentrationwas used, had
no significant effect on adhesion molecule expression.
Discussion
In the present study, we provide evidence of an inverse
relationship between adiponectin and CML levels in insulin resistant
overweight subjects and we identify adiponectin as a modulator of
endothelial dysfunction induced by AGEs.
Being overweight is the major risk factor for developing type 2
diabetes and cardiovascular disease. Many evidences suggest that
insulin resistance and obesity are closely correlated to endothelial
dysfunction and development of cardiovascular disease (Meyers et al.,
2007; Pierce et al., 2008), but the underlying mechanisms remain in
part unknown. In particular, the endothelial dysfunction in over-
weight/obese adults is related to increased abdominal visceral fat that
contributes directly or indirectly to impaired endothelial function by
releasing proinflammatory cytokines and adipokines, such as leptin,
inhibiting adiponectin release and increasing oxidative stress (Wil-
liams et al., 2002). A relationship between hypoadiponectinemia and
endothelial dysfunction has been previously shown in overweight
patients (Shimabukuro et al., 2003), demonstrating that loss of
adiponectin effects enhanced endothelial injury in obese people.
Subjects withmore elevated levels of adiponectin present a significant
reduction of the risk of myocardial infarction (Pischon et al., 2004). In
particular, decreased plasma adiponectin levels were related to the
development of coronary artery disease (CAD), suggesting that its
measurement may be helpful in assessment of CAD risk (Ouchi et al.,
1999). However, it has been observed that the heart volume in obese
mice overexpressing adiponectin, but metabolically healthy, was
significantly larger than that of obese mice, suggesting that excess
adiponectin leads to cardiomyopathy. Whether this effect is a direct
effect of increased adiponectin levels or the result of the overall
increase in weight is not known to date (Kim et al., 2007). The link
between adiponectin and endothelial dysfunction in different path-
ological conditions may be also explained by its anti-atherogenic and
anti-inflammatory properties (Ouchi et al., 1999; Ouchi et al., 2000;
Plant et al., 2008). Data in vitro have demonstrated that adiponectin
modulates the vascular response to lipid and inflammatory stimuli,
such as TNF-α, inhibiting the activation of endothelial nucleartranscription factor (NF-κB signaling), involved in the adhesion
molecule expression (Ouchi et al., 2000), and the production of
reactive oxygen species in hyperglycemic conditions (Ouedraogo et
al., 2006).
Since our results show that, in overweight patients, there is an
inverse correlation between adiponectin and CML levels, it is possible
to speculate that the down-regulation of adiponectin, related to the
presence of insulin resistance and obesity, may be a critical factor in
the development of endothelial dysfunction induced by AGEs. This
suggestion is also supported by our in vitro findings showing a
protective effect of physiologically concentration of adiponectin on
endothelial dysfunction induced by AGEs.
Endothelial dysfunction represents a key early step in atherogen-
esis, typically associated with decreased vasodilation and increased
expression of vascular adhesion molecules (Libby, 2002), and AGEs,
one of risk factors of endothelial dysfunction, are linked to increased
atherogenicity and inflammation. It is known that AGEs induce the
expression of endothelial adhesionmolecule (Basta et al., 2002). Thus,
interaction of AGEs with endothelial cells, as well as with other cells
accumulating within the atherosclerotic plaque, provides a mecha-
nism to augment vascular dysfunction.
Obesity has an inflammatory component, but interestingly, there
are no studies on the relationship between AGEs levels and metabolic
features of overweight/obesity.
It has been demonstrated that, in healthy subjects, plasma levels of
soluble form of RAGE (sRAGE), a receptor which acts as a decoy for
AGEs, were negatively correlated with BMI, and plasma sRAGE was
significantly lower in overweight subjects free of diabetes compared
to lean subjects supporting a possible protective role for this receptor
before any evidence of diabetic or vascular complications (Norata
et al., 2009).
A recent study has demonstrated a possible link between AGEs and
obesity showing that low caloric diet reduces AGEs levels in obese
Japanesemen plausibly by a reduction in glycation/lipoxidation due to
the caloric restriction or the decreased intake of food containing
glycotoxins. Likewise, it has been demonstrated that a meal with high
AGEs content decreases postprandial adiponectin and leptin levels
(Stirban et al., 2008). In vitro data have shown that AGEs impair the
leptin secretion (Unno et al., 2004). However, the details of the
mechanisms involved remain unknown.
Our findings suggest that adiponectin exerts a protective effect
against the endothelial dysfunction induced by AGEs, at least in part,
by decreasing adhesion molecule expression, and provides direct
evidence of the protective role of adiponectin in the pathogenesis of
the vascular complications of obesity/metabolic syndrome. However,
further investigation is needed to elucidate the intracellular signals by
which physiological concentrations of adiponectin suppresses AGE-
induced adhesion molecule expression, so to provide insight into
therapies.
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